Feb 5, 2024 | Press Releases
Patient Reported Outcomes (PROs) based on a May 16, 2022 data cutoff in the QUILT 3.032 trial indicate stability of physical function and global health in patients who completed PRO questionnaires and reached month 24 on-study Overall, participants with complete...
Jan 2, 2024 | Press Releases
Up to $300 million non-dilutive capital exchanged for royalty payments on future ImmunityBio immunotherapy product revenue with up to a $20 million equity investment Royalty financing includes $200 million funded at closing, and $100 million to be funded contingent...
Nov 22, 2023 | Press Releases
CULVER CITY, Calif., November 16, 2023 — ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 35th Annual Piper Sandler Healthcare Conference, which is taking place in New York City,...
Nov 7, 2023 | Press Releases
Findings from NCI-led study suggest that Memory Cytokine-Enriched Natural Killer cells (M-ceNK) may provide benefit to patients with small cell lung cancer and patients with other types of neuroendocrine tumors M-ceNK may provide an additional line of therapy in other...
Oct 26, 2023 | Press Releases
BLA for N-803 plus BCG in high-risk non-muscle-invasive bladder cancer (NMIBC) was resubmitted to the Agency on October 23, 2023 A new PDUFA date of April 23, 2024 has been communicated by the Agency CULVER CITY, Calif., October 26, 2023 — ImmunityBio, Inc. (NASDAQ:...
Oct 23, 2023 | Press Releases
Provides updated data on prolonged duration of complete response in BCG-Unresponsive and BCG-Naïve NMIBC patients Following the Type A Meeting with the FDA, ImmunityBio has completed the BLA resubmission addressing the issues in the Complete Response Letter. As part...
